Last reviewed · How we verify
Symlin® and Humulin® — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Symlin® and Humulin® (Symlin® and Humulin®) — Adocia.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Symlin® and Humulin® TARGET | Symlin® and Humulin® | Adocia | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Symlin® and Humulin® CI watch — RSS
- Symlin® and Humulin® CI watch — Atom
- Symlin® and Humulin® CI watch — JSON
- Symlin® and Humulin® alone — RSS
Cite this brief
Drug Landscape (2026). Symlin® and Humulin® — Competitive Intelligence Brief. https://druglandscape.com/ci/symlin-and-humulin. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab